Magnus Medical Highlights New Clinical Data on Groundbreaking SAINT Therapy at 2024 NYC Neuromodulation Conference
01 Agosto 2024 - 8:01AM
Business Wire
New Research shows promising, sustained results
for personalized treatment of treatment-resistant depression
Magnus Medical, Inc., a pioneering therapeutic neuromodulation
company transforming the treatment of neuropsychiatric disorders,
today announced promising new clinical data on SAINT® therapy at
the 2024 NYC Neuromodulation Conference, Aug 1-3. The research will
be presented in two posters demonstrating the long-lasting benefits
of SAINT treatment and its potential for personalized continuation
therapy in people with treatment-resistant depression (TRD).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240801284830/en/
SAINT® therapy works by leveraging
structural and functional magnetic resonance imaging (MRI) scans to
inform a proprietary algorithm that pinpoints the optimal
anatomical target for precise neurostimulation in individuals with
major depression. The innovative treatment is performed on an
accelerated, five-day timeline, ensuring that stimulation targeting
is meticulously customized to each person’s unique brain
connectivity. (Photo: Business Wire)
“We’re excited to share these new findings at this year’s NYC
Neuromodulation Conference, which further validate the
transformative potential of the SAINT therapy in providing durable
relief for people with debilitating intractable depression and
offering a pathway for personalized continuation treatment to
maintain remission,” said Brandon Bentzley, M.D., Ph.D., co-founder
and CSO, Magnus Medical. “The potential life-saving impact is truly
inspiring.”
“Furthermore, building on the strength of this compelling
research, we are rapidly expanding access to the SAINT
neuromodulation system, delivering it to hospitals and private
clinics across the country,” continued Dr. Bentzley.
Research Highlights:
- Durability of clinical benefit with Stanford Neuromodulation
Therapy (SNT, commercially known as SAINT) in treatment-resistant
depression: assessment of sustained remission and response
following index treatment
This study, conducted by researchers at Stanford University,
provides the first longer-term data on the durability of SAINT's
antidepressant effect in patients with TRD. The results indicate
that a single five-day course of treatment offers substantial and
durable clinical benefits, with patients remaining in remission for
an average of 11 weeks and in a state of response for an average of
15 weeks.
- An Open-Label Pilot Trial to Assess the Feasibility of Using
the Magnus Neuromodulation System with Stanford Accelerated
Intelligent Neuromodulation Therapy (SAINT) as a Personalized
Continuation Therapy for Depression
This study, led by Magnus Medical with Acacia Clinics,
investigated the use of SAINT as a personalized continuation
therapy for people with TRD who initially responded to an acute
course of SAINT treatment. The results demonstrate that this
approach is safe, well-tolerated, and highly effective in
maintaining remission from depression for 12 months.
Treatment with SAINT changes a person’s brain circuitry to treat
major depression more effectively by modifying activity in brain
networks that are related to depression. Granted Breakthrough
Device Designation and 510(k) clearance by the U.S. Food & Drug
Administration (FDA), SAINT therapy has led to dramatic
improvements in people’s symptoms of severe depression in a
clinical setting.
SAINT therapy works by leveraging structural and functional
magnetic resonance imaging (MRI) scans to inform a proprietary
algorithm that pinpoints the optimal anatomical target for precise
neurostimulation in individuals with major depression. The
innovative treatment is performed on an accelerated, five-day
timeline, ensuring that stimulation targeting is meticulously
customized to each person’s unique brain connectivity.
About Magnus
Magnus Medical, Inc., is a privately held therapeutic
neuromodulation company driven to transform lives by restoring
mental health. Co-founded in 2020, the company’s first product is
the SAINT neuromodulation system, which provides a new form of
individualized neurostimulation for treatment-resistant depression
indicated for adults who have failed to achieve satisfactory
improvement from prior antidepressant medications. For more
information, visit https://www.magnusmed.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240801284830/en/
amy@magnusmed.com Media resources +1 925.222-5094